Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.
- Published In:
- Med (New York, N.Y.), 6(2), 100570 (2025)
- Authors:
- Hellenkamp, Kristian, Sato, Ryosuke, von Haehling, Stephan(3)
- Database ID:
- RPEP-11352
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11352APA
Hellenkamp, Kristian; Sato, Ryosuke; von Haehling, Stephan. (2025). Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.. Med (New York, N.Y.), 6(2), 100570. https://doi.org/10.1016/j.medj.2024.12.004
MLA
Hellenkamp, Kristian, et al. "Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.." Med (New York, 2025. https://doi.org/10.1016/j.medj.2024.12.004
RethinkPeptides
RethinkPeptides Research Database. "Reaching the SUMMIT? Benefits and potential risks associated..." RPEP-11352. Retrieved from https://rethinkpeptides.com/research/hellenkamp-2025-reaching-the-summit-benefits
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.